Table 2 Current chemotherapy regimensa
APF530 250 mg | APF530 500 mg | Palonosetron 0.25 mg | |
|---|---|---|---|
MEC regimens, n (%) | n = 149 | n = 140 | n = 134 |
Docetaxel-trastuzumab | 0 | 1 (0.7) | 2 (1.5) |
Doxorubicin | 1 (0.7) | 1 (0.7) | 1 (0.7) |
Cyclophosphamide-anthracycline | 121 (81.2) | 108 (77.1) | 102 (76.1) |
Cyclophosphamide-docetaxel | 7 (4.7) | 7 (5.0) | 13 (9.7) |
5-FU-cyclophosphamide-methotrexate | 10 (6.7) | 11 (7.9) | 5 (3.7) |
Docetaxel-epirubicin | 4 (2.7) | 3 (2.1) | 3 (2.2) |
HEC regimens, n (%) | n = 60 | n = 67 | n = 58 |
Cyclophosphamide-doxorubicin | 2 (3.3) | 3 (4.5) | 0 |
5-FU-cyclophosphamide-anthracycline | 29 (48.3) | 33 (49.3) | 33 (56.9) |
Cyclophosphamide-docetaxel-doxorubicin | 15 (25.0) | 10 (14.9) | 7 (12.1) |
Carboplatin-docetaxel-trastuzumab | 5 (8.3) | 5 (7.5) | 5 (8.6) |
Carboplatin-docetaxel | 2 (3.3) | 5 (7.5) | 4 (6.9) |
Carboplatin-paclitaxel | 0 | 4 (6.0) | 2 (3.4) |
Carboplatin-gemcitabine | 1 (1.7) | 2 (3.0) | 1 (1.7) |